Drug intelligence / Profile preview

Aurex-3

Development stage
Unknown
Lead developer
Aurex International
Modality
Small Molecules
Administration
Oral
01

Overview

Aurex-3 is a dietary supplement containing concentrated omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), derived from fish oil. It is primarily indicated for the management of hypertriglyceridemia and as a supportive treatment for cardiovascular health. The mechanism of action involves the activation of peroxisome proliferator-activated receptors (PPARs), particularly the alpha isoform, which enhances the expression of genes involved in fatty acid oxidation and reduces the hepatic synthesis of very-low-density lipoproteins (VLDL). Additionally, omega-3 fatty acids inhibit sterol regulatory element-binding protein-1c (SREBP-1c), leading to decreased lipogenesis. Aurex-3 also possesses anti-inflammatory properties by shifting the production of eicosanoids from pro-inflammatory series-2 prostaglandins and series-4 leukotrienes to less inflammatory series-3 and series-5 variants, thereby improving endothelial function and reducing systemic inflammation.

Brand names
Aurex-3Aurex3Aurex 3
Other names
Omega-3 fatty acidsOmega3 fatty acidsOmega 3 fatty acidsFish oil
02

Targets

SREBP-1 / SREBF1 (SREBP-1)PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on Aurex-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurex-3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call